BiomX Inc. will host a conference call on May 15, 2025, to discuss Q1 2025 financial results and updates.
Quiver AI Summary
BiomX Inc., a clinical-stage company focused on developing natural and engineered phage therapies to combat specific pathogenic bacteria, announced a conference call and live audio webcast scheduled for May 15, 2025, at 2:00 p.m. ET. During this event, the company will share its financial results for the first quarter of 2025 and provide updates on its business and programs. Participants can join the call by dialing specific numbers for U.S. and international callers, and the webcast will be accessible in the Investors section of BiomX's website. The company utilizes its BOLT platform to create customized phage compositions targeting harmful bacteria in the treatment of chronic diseases. For further details, the company's website is available for reference.
Potential Positives
- BiomX is advancing novel phage therapies, positioning itself at the forefront of innovative treatments for chronic diseases with substantial unmet needs.
- The upcoming conference call and live audio webcast signal transparency and engagement with investors, highlighting the company's commitment to keeping stakeholders informed.
- Reporting first quarter 2025 financial results allows the company to demonstrate its financial health and progress, which is crucial for investor confidence.
- The use of proprietary technology (BOLT platform) showcases BiomX's unique approach to addressing bacterial infections, potentially distinguishing it from competitors in the field.
Potential Negatives
- None
FAQ
When will BiomX announce its first quarter 2025 financial results?
BiomX will announce its first quarter 2025 financial results on May 15, 2025, at 2:00 p.m. ET.
How can I participate in the BiomX conference call?
To participate in the conference call, dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International).
Where can I find the archived webcast of BiomX's conference call?
The archived webcast will be available in the Investors section of BiomX's website at www.biomx.com.
What is BiomX's focus in the biotechnology sector?
BiomX focuses on developing natural and engineered phage therapies to target and eliminate harmful bacteria.
What is the BOLT platform developed by BiomX?
The BOLT platform stands for BacteriOphage Lead to Treatment, used to customize phage compositions against specific bacterial targets.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PHGE Hedge Fund Activity
We have seen 1 institutional investors add shares of $PHGE stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAROLINA WEALTH ADVISORS, LLC added 159 shares (+inf%) to their portfolio in Q1 2025, for an estimated $88
- JOHNSON & JOHNSON added 0 shares (+0.0%) to their portfolio in Q1 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com .
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit
www.biomx.com
, the content of which does not form a part of this press release.
BiomX, Inc.
Ben Cohen
Head Corporate Communications
[email protected]
